Hologic (HOLX) Azione Prezzo
Hologic Prezzo
Negli ultimi 19 anni Hologic ha aumentato il fatturato del 12,2% all'anno, raggiungendo 4,10 miliardi USD. L'utile per azione è cresciuto del 12,8% all'anno negli ultimi 19 anni. Per Hologic, il margine netto del 13,8% risulta in calo rispetto al 33,2% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Hologic è 77,52 USD, circa il 2,0% sopra il prezzo attuale di mercato. Su 23 analisti, 0 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Hologic Prezzo delle azioni
Hologic Azione e analisi azionaria
Domande frequenti sull'azione Hologic
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
The business model of Hologic Inc revolves around providing innovative diagnostic solutions, primarily focused on women's healthcare. Hologic develops and markets a wide range of medical devices and instruments, including imaging systems, surgical products, and molecular diagnostic assays. The company's products are designed to enable healthcare professionals to effectively screen, diagnose, and treat various conditions and diseases. Hologic is renowned for its advanced technologies in breast health, gynecology, and skeletal health, offering solutions that empower early detection and intervention. By constantly pushing the boundaries of medical technology, Hologic Inc remains committed to improving healthcare outcomes for women around the world.
Hologic Inc is primarily active in the healthcare industry, specifically in the field of diagnostic products and medical devices. With a focus on improving women's health, Hologic Inc develops and manufactures a wide range of innovative solutions. Their portfolio includes advanced imaging systems, molecular diagnostic assays, surgical instruments, and women's health screening tests. As a prominent player in the healthcare sector, Hologic Inc constantly strives to provide cutting-edge technologies and solutions to address various medical challenges.
Hologic Inc is a leading global healthcare and diagnostics company. Established in 1985, Hologic has excelled in providing innovative solutions for women's health, with a focus on early detection and treatment of breast and cervical cancers. The company's dedication to research and development has resulted in breakthrough technologies, including the introduction of the first 3D mammography system. Hologic has expanded its portfolio to include diagnostics, surgical and skeletal health, and GYN surgical products. With a strong commitment to advancing healthcare, Hologic Inc continues to make significant contributions to improving patient outcomes and quality of life.
Hologic Inc, a leading healthcare company, has achieved several significant milestones. In recent years, the company has made notable advancements in breast health solutions. They introduced the world's first 3D mammography system, which revolutionized breast cancer detection by providing clearer and more accurate images. Hologic Inc also developed the Genius™ 3D Mammography™ exam, proven to detect breast cancer at an earlier stage compared to 2D mammography alone. Furthermore, the company expanded its portfolio by acquiring Gen-Probe, a molecular diagnostics company, allowing Hologic Inc to offer a comprehensive range of diagnostic solutions. These milestones highlight Hologic Inc's commitment to innovation and improving women's healthcare outcomes.
Hologic Inc is primarily present in various countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Hologic Inc operates in Europe, including countries like Germany, France, Italy, and the United Kingdom. It also has a presence in Asia, particularly in countries such as China and Japan. Furthermore, Hologic Inc serves customers in Canada and Latin America, with a focus on countries like Mexico and Brazil. Overall, Hologic Inc has a global reach and aims to provide its products and services to diverse markets internationally.
Hologic Inc represents values of innovation, commitment to quality, and patient-centric approach. The corporate philosophy of Hologic Inc revolves around developing cutting-edge medical technologies to improve women's health outcomes. With a focus on providing accurate and reliable diagnostic solutions, Hologic Inc strives to empower healthcare professionals and patients alike. The company's dedication to research and development, evidence-based practices, and collaboration with healthcare experts reinforces its commitment to advancing healthcare for women globally. Hologic Inc's mission is to make a difference in people's lives through advanced healthcare solutions, making them a trusted and reliable leader in the industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 76,66 USD per l’azione Hologic (mediana: 77,52 USD), pari a +0,9 % rispetto all’ultimo prezzo. Il consenso si basa su 23 giudizi di analisti.
23 analisti valutano attualmente l’azione Hologic: 0 raccomandano l’acquisto, 20 la tenuta e 3 la vendita. Per il 2026 gli analisti si aspettano per Hologic ricavi pari a 4,24 miliardi USD e un utile per azione di 4,49 USD.
Convertita al tasso di cambio attuale, l’azione Hologic quota 67,81 EUR (76,01 USD).
L’azione Hologic (HOLX) è quotata su 9 borse, tra cui: NASDAQ (HOLX), London (0J5Q.L), SIX (Zürich) (HO1.SW), XETRA (HO1.DE), Frankfurt (HO1.F), München (HO1.MU), Düsseldorf (HO1.DU), Wien (HOLX.VI).
Hologic Inc is an international leading provider of medical technology products and solutions. The company, headquartered in Marlborough, Massachusetts, operates globally and is divided into four business segments: Diagnostics, Gynecology, Skeletal Health, and Aesthetics.
Il attesa fatturato di Hologic ammonta a 4,24 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Hologic ammonta a 1,01 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Hologic è attualmente 16,93. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Hologic.
Il rapporto prezzo/fatturato (P/S) di Hologic è attualmente 4,05. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Hologic.
Il Quality Score AlleAktien per Hologic è 1/10.
L'ISIN di Hologic è US4364401012. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Hologic è 879100. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Hologic è HOLX. Con questo simbolo di borsa vengono negoziate le azioni Hologic in borsa.
Azione Hologic
Gruppo di pari di Hologic
Hologic Ticker
Hologic FIGI
Altre metriche e analisi di Hologic in Deep Dive.
La nostra analisi azionaria dell'azione Hologic include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Hologic. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: